Get the Stockscreener App
0.00
100.00%
-8.28
After Hours:
8.45
8.45
+
Cybin Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Cybin Inc., a biotechnology company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Cybin U.S., and Natures Journey. The Serenity Life and Cybin U.S. segment engages in the research and development of psychedelic pharmaceutical products. The Natures Journey segment focuses on non-psychedelic medicinal mushroom nutraceutical products. It develops CYB001, a drug candidate that is in phase IIa/b for major depressive disorder; CYB003, a deuterated tryptamine preclinical program to treat alcohol use disorder; CYB004, a deuterated tryptamine preclinical program for therapy resistant psychiatric disorder; and CYB005, a phenethylamine preclinical program for psychiatry and neurology. The company offers its products through various form factors, such as capsules, powders, and effervescent tablets. Cybin Inc. is headquartered in Toronto, Canada.
See More
Previous Close:
$8.28
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$413.12M
Revenue:
-
Net Income/Loss:
$-52.07M
P/E Ratio:
0.00
EPS:
-0.2077
Net Cash Flow:
$-44.93M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$9.83
Cybin Inc Stock (CYBN) Company Profile
Name
Cybin Inc
Sector
Industry
Phone
908 764 8385
Address
100 King Street West, Suite 5600, Toronto
Compare CYBN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYBN
Cybin Inc
|
0.00 | 413.12M | 0 | -52.07M | -44.93M | -0.2077 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.13 | 122.71B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
770.79 | 82.91B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
771.53 | 50.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.24 | 43.42B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
322.37 | 38.98B | 4.98B | 69.60M | 525.67M | 0.5198 |
Cybin Inc Stock (CYBN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-02-26 | Initiated | Jefferies | Buy |
| Mar-13-25 | Initiated | Guggenheim | Buy |
| Nov-19-21 | Downgrade | Maxim Group | Buy → Hold |
Cybin Inc Stock (CYBN) Latest News
Profit Review: Can Brookfield Renewable Corporation disrupt its industry2025 Earnings Surprises & Verified Momentum Stock Alerts - baoquankhu1.vn
Helus Pharma appoints Dr. Freda Lewis-Hall to board of directors - Investing.com India
HELUS Pharma: Transitioning From Psychedelic Research To Late-Stage Clinical Neuroscience - Seeking Alpha
Helus Pharma (Nasdaq: HELP) brings former Pfizer CMO Lewis-Hall onto board - Stock Titan
Published on: 2026-02-25 04:37:15 - baoquankhu1.vn
Helus Pharma appoints former Pfizer chief medical officer to board of directors - marketscreener.com
Published on: 2026-02-24 19:40:53 - baoquankhu1.vn
Former Pfizer chief medical officer joins Helus mental health push - Stock Titan
Moving Averages: What hedge funds are buying Cybin IncJuly 2025 Short Interest & AI Forecasted Entry/Exit Points - baoquankhu1.vn
Day Trade: What is PFBCs revenue forecastJuly 2025 Sentiment & Risk Controlled Swing Alerts - baoquankhu1.vn
What are Cybin Inc.’s earnings expectationsWeekly Risk Summary & Low Volatility Stock Suggestions - mfd.ru
New Highs: What hedge funds are buying Cybin IncGap Up & Long-Term Growth Stock Strategies - baoquankhu1.vn
Cybin (Helus Pharma) Names Veteran Pharma Executive Michael Cola as CEO to Drive CNS Growth - The Globe and Mail
(CYBN) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Jeffries Highlight Cybin D/B/A Helus Pharma (HELP)'s Science-Driven Psilocybin Therapies as Key Growth Drivers - Finviz
Jeffries Highlight Cybin D/B/A Helus Pharma (HELP)’s Science-Driven Psilocybin Therapies as Key Growth Drivers - Yahoo Finance
Cybin stock surges after positive Phase 2a trial results for depression drug - Investing.com
Cybin Inc.Common Stock (Nasdaq:HELP) Stock Quote - The Chronicle-Journal
Helus gains on published data for psychedelic drug (HELP) - Seeking Alpha
Cybin stock surges after positive Phase 2a trial results for depression drug By Investing.com - Investing.com South Africa
Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder - Investing News Network
Single-dose DMT eases major depression in trial published in Nature Medicine - Stock Titan
Breakout Watch: Is Cybin Inc stock a hidden gemJuly 2025 Setups & Smart Swing Trading Alerts - baoquankhu1.vn
Here's Why We're Watching Cybin's (NASDAQ:HELP) Cash Burn Situation - Yahoo Finance
Is Cybin Inc. a cyclical or defensive stockSwing Trade & Low Risk Entry Point Guides - mfd.ru
What are Cybin Inc.’s recent SEC filings showing2025 Institutional Moves & High Accuracy Trade Alerts - mfd.ru
Travel Stocks: Is Cybin Inc forming a bullish divergenceQuarterly Market Summary & High Win Rate Trade Alerts - baoquankhu1.vn
Cybin (NASDAQ:HELP) Announces Earnings Results - MarketBeat
HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights - Investing News Network
Cybin (Helus Pharma) Posts Higher Assets, Equity and Losses in Q3 FY2026 SEC Filing - TipRanks
Helus Pharma (NASDAQ: HELP) widens loss while sharply increasing cash - Stock Titan
Published on: 2026-02-13 13:41:22 - mfd.ru
Can Cybin Inc. benefit from deglobalizationJuly 2025 Market Mood & Weekly Consistent Profit Watchlists - mfd.ru
Published on: 2026-02-12 21:19:30 - mfd.ru
Fed Meeting: Is Cybin Inc impacted by rising ratesStock Surge & Stepwise Entry/Exit Trade Alerts - baoquankhu1.vn
Ideas Watch: Is Cybin Inc impacted by rising rates2025 Market WrapUp & Safe Entry Trade Reports - baoquankhu1.vn
Is Cybin Inc. forming a breakout pattern2025 Trading Recap & Free Weekly Watchlist of Top Performers - mfd.ru
Will Cybin Inc. Common Shares stock benefit from sector leadershipDay Trade & Fast Entry and Exit Trade Plans - mfd.ru
Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution - wahanariau.com
Helus Pharma Appoints Michael Cola as Chief Executive Officer, Effective February 10, 2026 - marketscreener.com
New Helus Pharma CEO inherits mental health drug pipeline at key trial dates - Stock Titan
Will Helus Pharma's GAD Trial Data Calm Investor Anxiety? - RTTNews
How (CYBN) Movements Inform Risk Allocation Models - Stock Traders Daily
Bank Watch: Will Cybin Inc stock benefit from M AJuly 2025 Trends & High Win Rate Trade Tips - baoquankhu1.vn
Biggest stock movers Wednesday: Vanda Pharmaceuticals, Axsome Therapeutics and Cybin - MSN
Jefferies Financial Group Begins Coverage on Cybin (NASDAQ:HELP) - MarketBeat
Jefferies Initiates Coverage on Cybin With Buy Rating, CA$29.88 Price Target - marketscreener.com
Trend Recap: Does Cybin Inc stock have upside surprise potential2025 Top Gainers & Risk Controlled Stock Alerts - baoquankhu1.vn
Risk Report: Is PRCH stock technically oversoldExit Point & Smart Investment Allocation Tips - baoquankhu1.vn
Market Review: Does Cybin Inc stock have upside surprise potentialJuly 2025 Action & Reliable Entry Point Alerts - baoquankhu1.vn
Cybin Inc Stock (CYBN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
0.59%
Cap:
|
Volume (24h):